David Thompson
Corporate Officer/Principal at INOZYME PHARMA, INC.
David Thompson active positions
| Companies | Position | Start | End |
|---|---|---|---|
| INOZYME PHARMA, INC. | Corporate Officer/Principal | 30/06/2021 | - |
Career history of David Thompson
Former positions of David Thompson
| Companies | Position | Start | End |
|---|---|---|---|
| INOZYME PHARMA, INC. | Chief Tech/Sci/R&D Officer | 31/03/2018 | 12/10/2020 |
Azure Biotech, Inc.
 Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Founder | - | - |
| President | - | - |
Training of David Thompson
| The University of Montana | Graduate Degree |
| University of Connecticut | Doctorate Degree |
Statistics
International
| United States | 5 |
Operational
| Graduate Degree | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Azure Biotech, Inc.
Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Health Technology |
- Stock Market
- Insiders
- David Thompson
- Experience
